Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
Abstract Background Chemotherapy‐induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT. In our recent phase II randomized study, romiplostim led to correction of platelet coun...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2022-03-01
|
| シリーズ: | Research and Practice in Thrombosis and Haemostasis |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1002/rth2.12701 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|